BRAF and neoplasm: We hypothesize that the effectiveness of these drugs may depend on the activated oncogene abundance when the tumor is driven by two distinct driver genes, detecting the abundance of EGFR mutations and BRAF mutations is crucial for optimizing the selection of TKIs in clinical practice.